REFERENCES
- Bartsch W, Klein H, Schiemann U, Bauer HW, Voigt KD (1990): Enzymes of androgen formation and degradation in the human prostate. Ann N Y Acad Sci 595:53–66.
- Belanger A, Guillemette C, Hum DW (1996): Evidence for a role of glucuronosyltransferase in the regulation of androgen action in the human prostatic cancer cell line LNCaP. J Steroid Biochem Mol Biol 57:225–231.
- Belanger G, Beaulieu M, Marcotte B, Levesque E, Guillemette C, Hum DW, Belanger A (1995): Expression of transcripts encoding steroid UDP-glucuronosyltransferases in human prostate hyper-plastic tissue and the LNCaP cell line. Mol Cell Endocrinol 113:165–173.
- Camby I, Etievant C, Petein M, Dedecker R, van Velthoven R, Danguy A, Pasteels JL, Kiss R (1994): Influence of culture media on the morphological differentiation of the PC-3 and DU145 prostatic neoplastic cell lines. Prostate 24:187–196.
- Castagnetta L, Granata OM, Polito L, Blasi L, Cannella S, Carruba G (1994): Different conversion metabolic rates of testosterone are associated to hormone-sensitive status and -response of human prostate cancer cells. J Steroid Biochem Mol Biol 49:351–357.
- Ghanadian R, Masters JR, Smith CB (1981): Altered androgen metabolism in carcinoma of the prostate. Eur Urol 7:169–170.
- Guillemette C, Hum DW, Belanger A (1995): Specificity of glucuronosyltransferase activity in the human cancer cell line LNCaP, evidence for the presence of at least two glucuronosyltransferase enzymes. J Steroid Biochem Mol Biol 55:355–362.
- Guillemette C(1995): Glucuronosyltransferase activity in human cancer cell line LNCaP. Mol Cell Endocrinol 107:131–139.
- Guillemette C, Hum DW, Belanger A (1996): Regulation of steroid glucuronosyltransferase activities and transcripts by androgen in the human prostatic cancer LNCaP cell line. Endocrinology 137:2872–2879.
- Hum DW, Belanger A, Levesque E, Barbier O, Beaulieu M, Albert C, Vallee M, Guillemette C, Tchernof A, Turgeon D, Dubois S (1999): Characterization of UDP-glucuronosyltransferases active on steroid hormones. J Steroid Biochem Mol Biol 69:413–423.
- Koh Y, Buczko E, Dufau ML (1993): Requirement of phenylalanine 343 for the preferential delta 4-lyase versus delta 5-lyase activity of rat CYP17. J Biol Chem 268:18267–18271.
- Labrie F, Dupont A, Belanger A, Giguere M, Lacoursiere Y, Emond J, Monfette G, Bergeron V (1985): Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in ad-vanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem 23:833–841.
- Labrie F, Dupont A, Simard J, Luu-The V, Belanger A (1993): Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur Urol 24 (Suppl 2):94–105.
- Labrie F, Belanger A, Van LT, Labrie C, Simard J, Cusan L, Gomez JL, Candas B (1998): DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids 63:322–328.
- Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, Fournel-Gigleux S, Green M, Hum DW, Iyanagi T, Lancet D, Louisot P, Magdalou J, Chowdhury JR, Ritter JK, Schachter H, Tephly TR, Tipton KF, Nebert DW (1997): The UDP glycosyltransferase gene superfamily: recom-mended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255–269.
- Morfin RF, Leav I, Charles JF, Cavazos LF, Ofner P, Floch HH (1977): Correlative study of the morphology and C19-steroid metabolism of benign and cancerous human prostatic tissue. Cancer 39:1517–1534.
- Smith CB, Masters JR, Metcalfe SA, Ghanadian R (1983): Androgen metabolism by human prostatic tumours in organ culture. Eur J Cancer Clin Oncol 19:929–934.
- Smith CM, Ballard SA, Wyllie MG, Masters JR (1994): Comparison of testosterone metabolism in benign prostatic hyperplasia and human prostate cancer cell lines in vitro. J Steroid Biochem Mol Biol 50:151–159.